Search

Author/Creator Jacobsen, E. D.

1. P1172: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL: UPDATED EXPANSION PHASE ANALYSIS. (23rd June 2022)

Authors:
Zinzani, P. L.; Zain, J.; Mead, M.; Casulo, C.; Jacobsen, E. D.; Gritti, G.; Pinter-Brown, L.; Isutzu, K.; Cohan, D.; Daugherty, M.; Brammer, J. E.; Mehta-Shah, N.; Pro, B.; Horwitz, S. M.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1058
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. THE COMBINATION OF DUVELISIB AND ROMIDEPSIN (DR) IS HIGHLY ACTIVE AGAINST RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA WITH LOW RATES OF TRANSAMINITIS: FINAL RESULTS. (17th June 2021)

Authors:
Horwitz, S. M.; Moskowitz, A. J.; Mehta‐Shah, N.; Jacobsen, E. D.; Khodadoust, M. S.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Myskowski, P.; Maccaro, C.; Blouin, W.; Schwieterman, J.; Cathcart, E.; Fang, S.; Perez, L.; Ryu, S.; Galasso, N.; Straus, D.; Fisher, D. C.
Journal:
Hematological oncology
Issue:
Volume 39(2021)Supplement 2
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search